We are live on ! Find out more
SCMP

Sucampo Pharmaceuticals, Inc.
SCMP

Delisted

SCMP was delisted on the 12th of February, 2018.

167 hedge funds and large institutions have $272M invested in Sucampo Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 68 increasing their positions, 46 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

170% more call options, than puts

Call options by funds: $1.97M | Put options by funds: $730K

48% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 46

0% more funds holding

Funds holding: 167167 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 23

5% less capital invested

Capital invested by funds: $287M → $272M (-$14.9M)

Holders
167
Holders Change
Holders Change %
0%
% of All Funds
4.16%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
23
Increased
68
Reduced
46
Closed
23
Calls
$1.97M
Puts
$730K
Net Calls
+$1.24M
Net Calls Change
+$883K
Name Holding Trade Value Shares
Change
Change in
Stake
JP Morgan Chase
126
JP Morgan Chase
New York
$117K +$114K +11,141 New
FCBT
127
First Citizens Bank & Trust
North Carolina
$116K +$113K +11,093 New
T. Rowe Price Associates
128
T. Rowe Price Associates
Maryland
$110K
LSERS
129
Louisiana State Employees Retirement System
Louisiana
$107K +$1.02K +100 +1%
Barclays
130
Barclays
United Kingdom
$101K -$123K -12,102 -56%
Public Employees Retirement Association of Colorado
131
Public Employees Retirement Association of Colorado
Colorado
$88K
TRSOTSOK
132
Teachers Retirement System of the State of Kentucky
Kentucky
$84K
Lazard Asset Management
133
Lazard Asset Management
New York
$84K +$10.2K +1,000 +14%
BAM
134
Barrett Asset Management
New York
$82K
SGAM
135
Smith Group Asset Management
Texas
$76K -$34.3K -3,360 -32%
RA
136
Rational Advisors
New York
$70K +$68.3K +6,700 New
PCM
137
Prelude Capital Management
New York
$66K -$252K -24,749 -80%
MSA
138
Mason Street Advisors
Wisconsin
$65K +$4.08K +400 +7%
Simplex Trading
139
Simplex Trading
Illinois
$64K +$32.2K +3,155 +107%
AIM
140
Acrospire Investment Management
Illinois
$53K -$45.6K -4,469 -47%
SEI Investments
141
SEI Investments
Pennsylvania
$53K +$18.5K +1,817 +58%
PNC Financial Services Group
142
PNC Financial Services Group
Pennsylvania
$52K +$7.57K +743 +18%
LIA
143
LS Investment Advisors
Michigan
$52K +$40K +3,925 +377%
SOADOR
144
State of Alaska Department of Revenue
Alaska
$50K +$22.1K +2,164 +80%
PI
145
PineBridge Investments
New York
$34K +$775 +76 +2%
QT
146
Quantbot Technologies
New York
$29K +$1.68K +165 +6%
LTFS
147
Ladenburg Thalmann Financial Services
Florida
$24K +$907 +89 +4%
Creative Planning
148
Creative Planning
Kansas
$21K +$4.08K +400 +25%
AIP
149
Ameritas Investment Partners
Nebraska
$20K
BTIS
150
BB&T Investment Services
North Carolina
$16K +$5.85K +574 +60%

SCMP Hedge Fund Activity: Q2 2017 in Review

167 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q2 2017, worth a combined $272M — down 5.2% from $287M a quarter earlier.

Fund positioning in SCMP was balanced in Q2 2017: 23 funds opened new positions, 23 closed out, 68 added to existing stakes and 46 trimmed.

The largest buyer was NEA Management Company, opening a new position worth an estimated $12.8M. The largest seller was Redwood Investments, exiting entirely with an estimated $6.63M sold.

  • 167 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q2 2017, unchanged from Q1 2017.
  • Funds reported $272M of Sucampo Pharmaceuticals, Inc. stock for Q2 2017, down 5.2% quarter-over-quarter.
  • 23 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q2 2017 and 23 closed out, a net change of 0 holders.
  • The largest Sucampo Pharmaceuticals, Inc. buyer in Q2 2017 was NEA Management Company, an estimated $12.8M added.
  • The largest Sucampo Pharmaceuticals, Inc. seller in Q2 2017 was Redwood Investments, an estimated $6.63M sold.

Based on aggregated 13F filings for Q2 2017.